Epidemiology and Phylogenomic Characterization of Distinct 2023 and 2024 Mpox outbreaks in Kinshasa, Democratic Republic of the Congo - Evidence for increasingly sustained human-to-human transmission of subclade Ia

Tony Wawina-Bokalanga,Sydney Merritt,Eddy Kinganda Lusamaki,Daan Jansen,Megan Halbrook,Elisabeth Pukuta-Simbu,Aine O'Toole,Emmanuel Hasivirwe Vakaniaki,Rilia Ola-Mpumbe,Papy Kwete,Prince Akil-Bandali,Cris Kacita,Ange Ponga-Museme,Nelson Mapenzi-Kashali,Adrienne Amuri-Aziza,Olivier Tshiani-Mbaya,Princesse Paku-Tshambu,Pedro HLF Dantas,Tessa de Block,Emmanuel Lokilo,Chloe Muswamba,Jean-Claude Makangara-Cigolo,Gradi Luakanda,Christian Ngandu,David J. Kelvin,Catherine Pratt,Ahidjo Ayouba,Sofonias Tessema,Nicaise Ndembi,Antonio Mauro Rezende,Eric Delaporte,Dieudonne Mwamba,Lorenzo Subissi,Laurens Liesenborghs,Nicole A Hoff,Martine Peeters,Nicola Low,Steve Ahuka-Mundeke,Jean-Jacques Tamfum Muyembe,Anne W. Rimoin,Jason Kindrachuk,Koen Vercauteren,Andrew Rambaut,Mbala Placide
DOI: https://doi.org/10.1101/2024.11.15.24317404
2024-11-16
Abstract:Background: Monkeypox virus (MPXV) is endemic to the Democratic Republic of the Congo (DRC), and historically has been reported in rural, forested regions with limited household and primarily zoonotic transmission. With the emergence of subclade Ib and increasing reported human-to-human transmission of MPXV we sought to characterize both the epidemiologic and genomic characteristics of confirmed mpox cases in Kinshasa, DRC, following confirmed MPXV introduction in August 2023. Methods: This retrospective observational study leveraged demographic and case-investigation data, as well as biological samples, collected from suspected mpox cases in Kinshasa from January 2023 to September 2024 as part of routine national surveillance. Samples were tested at the Institut National de Recherche Biomedicale first by qPCR to confirm MPXV, and subsequently sequenced for genomic analysis for those samples with a cycle threshold value <31. Findings: Epidemiological characterization of all confirmed mpox cases in Kinshasa indicated two distinct periods of MPXV introduction and circulation: first, following the initial case in August 2023, self-limiting transmission chains of subclade Ia primarily among men. Case investigations from this period suggest human human transmission. The second period is marked by the introduction of subclade Ib to the city and expanded co-circulation of both subclades with Limete health zone reporting the most cases of both subclades. Of those samples sequenced, genomic analysis indicated that greater than 60% of mutations in both subclades were consistent with APOBEC3-driven mutations. Interpretation: These data suggest that as of July 2024, MPXV in Kinshasa has undergone an epidemiological shift with sustained human-to-human transmission and co-circulation of two distinct subclades. Additionally, high rates of APOBEC3-driven changes further support this shift towards human-to-human transmission. While sexual-contact transmission cannot be confirmed without further case investigation, these data highlight important changes in mpox dynamics which may better guide mpox mitigation and containment strategies in Kinshasa.
Infectious Diseases (except HIV/AIDS)
What problem does this paper attempt to address?